Cancer, Tumors, Carcinoma
Conditions
Interventions
investigational material(s)
Generic name etc : AZD4877
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material
Sponsors
AstraZeneca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Ages Eligible for Study: 20 Years to 75 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No Inclusion Criteria: -Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments. -Patients who usually have mild symptoms capable of walking and light and sedentary work. -Patients who can stay in hospital at least during 4 weeks. Exclusion Criteria: -Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin. -Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function. -Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies | — |
Outcome results
None listed